HAART-related nephropathies in HIV-infected patients.
There is no doubt that highly active antiretroviral therapy (HAART) has been the most important progress in the therapy of human immunodeficiency virus (HIV)-infected patients in the last decade. A growing number of observations suggest that the beneficial effects of HAART also include improvement of HIV-related renal complications. Consequently, the cohort of HIV-infected patients requiring HAART has increased and includes patients with preexisting nephropathies, whether related or unrelated to HIV infection. However, some antiretroviral drugs may have renal- and life-threatening side-effects, especially if underlying renal abnormalities exist. In this review, we focus on those aspects that require particular attention in preventing new health complications in HIV-infected patients.
Daugas
Eric
E
Service de Nephrologie B, Hôpital Tenon, AP-HP, Paris, France. eric.daugas@tnn.ap-hop-paris.fr
Rougier
Jean-Philippe
JP
Hill
Gary
G
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D007684:Kidney Tubules / Q000187:drug effects / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D014779:Virus Replication
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors